Anebulo Pharmaceuticals, Inc. (ANEB) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Lakeway, TX, United States. The current CEO is Richard Anthony Cunningham.
ANEB has IPO date of 2021-05-07, 2 full-time employees, listed on the Other OTC, a market capitalization of $20.39M.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
